secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001628280-26-009476
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals
--------------------------------------------------------------------------------

- Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.
- More than 36,250 patients on Rezdiffra as of year-end 2025.
- Cash, equivalents and marketable securities $988.6M as of Dec. 31, 2025.
- Licensed global rights to six pre-clinical siRNA programs and oral GLP-1 (MGL-2086) to combine with Rezdiffra.
- Secured Orange Book listed Rezdiffra patent with protection into 2045; also closed $500M credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/0001628280-26-009476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/mdgl-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-009476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer